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of end stage renal disease, AMI or stroke are likely to re-
sult in substantial cost-offsets.
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OBJECTIVE: The UK Prospective Diabetes Study (UKPDS)
has proven the relevance of an intensive glucose control
policy in type 2 diabetes. UKPDS 35 has provided the evi-
dence of a significant association between diabetes-related
complications and level of HbA1c. We used the UKPDS
findings to assess the cost-effectiveness of a new fixed-dose
combination of metformin and glibenclamide, compared
to the conventional strategy of the UKPDS.
METHODS: We developed a Markov model reflecting
the management of two diabetic cohorts. The follow-up
of a cohort of newly diagnosed 50-year-old patients, sim-
ilar to the conventional group of the UKPDS, was simu-
lated to follow HbA1c progression over a 10-year period.
The second cohort, treated with metformin-glibencla-
mide, had the same demographic and clinical characteris-
tics at baseline. The reduction rate of HbA1c under met-
formin-glibenclamide was extracted from a 20-week
randomized double-blind trial. The HbA1c level in the
metformin-glibenclamide cohort was assumed to progres-
sively converge with that in the conventional group. The
occurrence of complications was modeled through risk
functions linking HbA1c levels to a conditional probabil-
ity using UKPDS 23 and 35 results. Results were com-
puted in a French context using a payer perspective. Only
medical costs were considered. A sensitivity analysis was
performed on the reduction rate of HbA1c under met-
formin-glibenclamide between 0.8 (best case) and 1.5
(worst case).
RESULTS: Cumulative medical costs amounted to EUR
7,240 in the conventional group versus EUR 7,759 in the
metformin-glibenclamide group. A 6.1% decrease in the
mean number of events per patient was obtained. The ad-
ditional cost per life year saved was EUR 13,142 (9,924
(best case), 17,912 (worst case)) and the additional cost
per complication-free year was EUR 5,736 (4,312 (worst
case), 7,842 (best case)).
CONCLUSION: These results suggest that metformin-
glibenclamide is cost-effective in the treatment of type 2
diabetes when compared with conventional therapy.
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OBJECTIVE: To assess the cost-effectiveness of pioglita-
zone (PIO) based combinations versus alternatives for pa-
tients with type 2 diabetes in Norway.
METHODS: A published/validated model for type1 dia-
betes developed by IMIB was adapted to simulate long-
term management, health outcomes, resource utilisation
and treatment costs of patients with type2 diabetes. The
model accounts for most complications in diabetes pa-
tients: nephropathy; retinopathy; acute myocardial in-
farction; angina pectoris; stroke, and amputation. The
analysis was done from third-party-payer perspective and
costs figured relative to the year 2000. A 5% discount
rate was applied and sensitivity analysis was done to test
the results.
RESULTS: Pioglitazone PIO 30 mg and metformin (MF)
were associated withlonger life expectancy (16.10 years)
than sulphonylureas(SU)/MF (15.24) or rosiglitazone
(RSG)/MET (15.95). PIO 30 mg/SU and PIO 15 mg/SU
are associated with the lowest number of serious compli-
cations per 100 patients treated. For every 95 patients
treated with PIO 30 mg/MF rather than SU/MF or every
27 patients, respectively, for PIO,30 mg/SU rather MF/SU,
one complication is avoided. Combinations of PIO 30
mg/SU, PIO 30 mg/MF and PIO 15 mg/SU are associated
with lower mortality than the other treatment combina-
tions available. Thus, for every 34 patients treated with
PIO 30 mg/MF rather than SU/MF, one death will be
avoided after 15 years of treatment. After discounting
both costs and life years at 5%, the above incremental
cost-per-life-year is 29,406 Norway Kroner (NOK) in
comparison to SU/MF, but still PIO dominates the com-
bination therapy with RSG 8 mg. The picture is similar in
the case of PIO 30 mg/SU combination compared to
MFSU, where in the undiscounted incremental cost per
life year gained, PIO dominates, and the cost per life year
gained is raised to 25,992 NOK after discounting at 5%.
CONCLUSION: Pioglitazone-based treatment for pa-
tients with type2 diabetes improves survival and reduces
complications and therefore represents a cost-effective
use of health-care resources in Norway. Nonetheless,
these results must be confirmed by long-term observa-
tional studies.
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OBJECTIVE: The objective of this study is to assess the
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long-term clinical benefits and cost-offsets of oral dia-
betic management with nateglinide in combination with
metformin vs. metformin alone in the Netherlands.
METHODS: Data from clinical trials and epidemiologi-
cal studies have been incorporated in a diabetes model
that dynamically relates patient characteristics (demo-
graphics, cardiovascular risk factors, diabetes history)
and glycemic control to diabetic complications. In the
model, a cohort of 10,000 patients was followed over a
30-year period for the occurrence of diabetic complica-
tions, its associated treatment costs and mortality. The
impact of improved glycemic control (HbA1c and post-
prandial glucose or PPG) was modeled using results from
a clinical trial.
RESULTS: An incremental reduction in HbA1c of 0.7%
and of PPG by 1.4mmol/L of nateglinide combination
therapy will reduce the number of patients with end-stage
renal disease (ESRD), blindness and lower-extremity am-
putation by 168, 169 and 197 respectively. Another 78
cases of AMI and 38 cases of cerebral stroke will be
avoided. This will result in cost-offsets of NLG 6,527 per
patient on average, mainly due to ESRD (72%), stroke
(6%), amputation (6%) and blindness (5%). The esti-
mated life expectancy increases by 0.33 years (0.2 years if
discounted at 4%). The model was robust for changes in
critical assumptions.
CONCLUSION: Improved glycemic control as achieved
with combination therapy of nateglinide plus metformin
will substantially reduce the number of diabetic compli-
cations and associated treatment costs over treatment
with metformin alone in the Netherlands.
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OBJECTIVES: To assess antidiabetic treatment and asso-
ciated costs of patients with type 2 diabetes in Germany.
METHODS: In a cost-of-illness study based on a repre-
sentative sample of 809 patients with type 2 diabetes,
treatment strategies, overall resource use and cost were
investigated for the year 1998. This analysis is centred on
the question of how the antidiabetic treatment influences
resource use and cost. Taking the perspective of the statu-
tory health insurance, overall direct and indirect health-
care costs for diabetes patients were investigated.
RESULTS: Among all patients, 19% were treated with
diet and exercise only, 53% received oral anti-diabetics
(OAD) and 28% were insulin recipients. The three treat-
ment groups differed in terms of time since diagnosis of
diabetes and complication status, with the most severe
cases in the insulin group. Total costs were highest for
patients taking insulin and amounted to 4,100 Euro. For
patients on diet/exercise and on OAD, total costs were
2242 Euro and 2184 Euro, respectively. Similarly, the
cost of medication was also highest for patients taking in-
sulin (1296 Euro) compared to patients on OAD (576
Euro) or diet (484 Euro). The cost of hospitalization and
rehabilitation was approximately half the total cost in
each group (insulin 2166 Euro, OAD 1105 Euro, diet
1047 Euro). Patients on diet had similar total and inpa-
tient costs as patients on OAD, but had the highest indi-
rect cost. A regression analysis was used to determine the
influence of treatment type, time since diagnosis of diabe-
tes, and complication status on total costs. Insulin treat-
ment and complication status had a significant impact
(p  .0001) on total costs whereas time since diagnosis
and other treatment types had none.
CONCLUSIONS: The disease progression is reflected by
the change in antidiabetic treatment. The highest costs
were observed in patients treated with insulin. These pa-
tients also experience more severe complications.
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OBJECTIVE: To assess the cost-effectiveness of pioglita-
zone (PIO) in combination therapy versus usual care for
patients with type 2 diabetes.
METHODS: A published, validated model for type1 dia-
betes mellitus developed by the Institute of Medical In-
formatics and Biostatistics was adapted to simulate long-
term management, health outcomes, resource utilisation
and treatment costs of patients with type 2 diabetes. The
model accounts for most complications occurring in dia-
betes patients: nephropathy; retinopathy; acute myocar-
dial infarction; angina pectoris; stroke, and amputation.
The analysis was done from a third-party-payer perspec-
tive and costs figured relative to the year 2000. A 3% dis-
count rate was applied to costs and outcomes and sensi-
tivity analysis was performed to test the results.
RESULTS: PIO 30 mg in combination with metformin
(MF) was associated with a longer life expectancy (14.06
years) than sulphonylureas (SU)/MF (13.49 years) or
rosiglitazone (RSG) 8 mg/MF (13.98 years). PIO-based
combinations were associated with the lowest number of
complications and deaths. For every 38 patients treated
with PIO 30 mg/MF rather than SU/MF or every 37 pa-
tients, respectively, for PIO 15 mg/SU rather than MEF/SU,
one complication was avoided. Also, for every 39 patients
